Ozempic, Wegovy, other GLP-1RA drugs not linked to increased pancreatic cancer risk, study finds
Posted:
New research has concluded that drugs from the glucagon-like peptide-1 receptor agonists (GLP-1RA) class do not increase the risk of pancreatic cancer.
Behind every successful ecosystem is a group of experts helping shape its direction, ensure relevance, and maintain its focus on real-world impact.
At GIANT Health, this role is fulfilled by our Board of Advisors — a distinguished group of senior…
Procurement is no longer just a back-office function in healthcare — it is one of the most powerful levers shaping how the NHS adopts innovation, improves efficiency, and delivers better outcomes for patients.
At the heart of this transformation is…
Attendees
Sponsors and Exhibitors
Contact us